Document is current
Any future updates will be listed below
-
Authors
Sharifnia, Tanaz https://orcid.org/0000-0001-7274-164X
Wawer, Mathias J. https://orcid.org/0000-0001-6664-0930
Goodale, Amy
Lee, Yenarae
Kazachkova, Mariya
Dempster, Joshua M. https://orcid.org/0000-0002-3634-9576
Muller, Sandrine
Levy, Joan
Freed, Daniel M.
Sommer, Josh
Kalfon, Jérémie
Vazquez, Francisca
Hahn, William C. https://orcid.org/0000-0003-2840-9791
Root, David E. https://orcid.org/0000-0001-5122-861X
Clemons, Paul A. https://orcid.org/0000-0002-1800-5112
Schreiber, Stuart L. https://orcid.org/0000-0003-1922-7558
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA176058, U01CA217848)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Chordoma Foundation (500244)
- License Information
-
More Information
Article History
Received: 31 May 2022
Accepted: 21 March 2023
First Online: 6 April 2023
Competing interests
: M.J.W. is an employee and shareholder of Kojin Therapeutics. D.M.F. is a consultant for Incyclix Bio. F.V. receives research support from the Dependency Map Consortium, Bristol Myers Squibb, Novo Ventures, and Riva therapeutics, has participated in an advisory board of GSK, and has shares and is a consultant for Riva Therapeutics. D.E.R. receives research funding from members of the Functional Genomics Consortium (Abbvie, Bristol-Myers Squibb, Jannsen, Merck, Vir), and is a director of Addgene, Inc. W.C.H. is a consultant for ThermoFisher, Solasta, MPM Capital, Frontier Medicines, Tyra Biosciences, RAPPTA Therapeutics, KSQ Therapeutics, Jubilant Therapeutics, Function Oncology, Calyx, and Serinus Biosciences. P.A.C. is an advisor to Pfizer, Inc., Belharra Therapeutics, and Magnet Biomedicine. S.L.S. is a shareholder and serves on the Board of Directors of Kojin Therapeutics; is a shareholder and advises Jnana Therapeutics, Kisbee Therapeutics, Belharra Therapeutics, Magnet Biomedicine, Exo Therapeutics, Eikonizo Therapeutics, and Replay Bio; advises Vividian Therapeutics, Eisai Co., Ltd., Ono Pharma Foundation, F-Prime Capital Partners, and the Genomics Institute of the Novartis Research Foundation; and is a Novartis Faculty Scholar. The remaining authors declare no competing interests.
